Tanvi H Patel

Researcher

UAMS

Also affiliated: Baptist Health Foundation (2021); Winthrop Rockefeller Foundation (2023–2024)

Faculty Researcher

4 h-index 13 pubs 55 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Tanvi H Patel's research focuses on multiple myeloma and related hematologic malignancies. Her work investigates therapeutic strategies, including CAR T-cell therapy and novel agents like mezigdomide and iberdomide, which target the cereblon E3 ligase complex. Patel has also examined prognostic factors, such as immune scores, for predicting outcomes in relapsed multiple myeloma patients treated with bispecific antibodies. Her publications include studies on the psychological impact of monoclonal gammopathy and smoldering multiple myeloma, as well as case reports on rare presentations of multiple myeloma and other conditions. She has authored 13 publications, with an h-index of 4 and 48 total citations. Her collaborations include 14 shared publications with Ramya Bachu and 8 shared publications with Tanvi Patel, both at the University of Arkansas for Medical Sciences.

Metrics

h-index: 4
Publications: 13
Citations: 55

Selected Publications

Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)

Frontiers in Hematology 1 citation DOI OpenAlex
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP) (2024)

Blood DOI OpenAlex
Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM) (2024)

Blood 2 citations DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)

Clinical Hematology International 12 citations DOI OpenAlex
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies (2024)

British Journal of Haematology 3 citations DOI OpenAlex
Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma (2024)

Clinical Lymphoma Myeloma & Leukemia 12 citations DOI OpenAlex
Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma. (2024)

Journal of Clinical Oncology 2 citations DOI OpenAlex
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (2024)

Bone Marrow Transplantation 25 citations DOI OpenAlex
A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma (2024)

Transplantation and Cellular Therapy 1 citation DOI OpenAlex
Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm (2024)

Cureus DOI OpenAlex
The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T in Multiple Myeloma (2023)

Blood 1 citation DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2023)

Blood DOI OpenAlex
Necrotizing Enterocolitis in a Patient With Newly Diagnosed Multiple Myeloma and Hyperviscosity Syndrome: A Case Report (2023)

Cureus 1 citation DOI OpenAlex
Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature (2023)

Cureus 2 citations DOI OpenAlex
A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers (2023)

Onco 12 citations DOI OpenAlex